FDA Advisory Committee to Review Capricor's Duchenne Muscular Dystrophy Therapy — Capricor Therapeutics, Inc.

Event summary

Capricor Therapeutics' FDA advisory committee meeting scheduled for July 29, 2026 to review Deramiocel's BLA for Duchenne Muscular Dystrophy.
BLA supported by Phase 2 HOPE-2 trial and long-term outcomes from HOPE-2-OLE trial, as well as positive results from Phase 3 HOPE-3 trial.
Deramiocel has received Orphan Drug Designation, RMAT designation, ATMP designation, and Rare Pediatric Disease Designation.
PDUFA target action date for Deramiocel is August 22, 2026.

The big picture

Capricor Therapeutics is advancing its lead product candidate, Deramiocel, through the regulatory process for the treatment of Duchenne Muscular Dystrophy. The upcoming FDA advisory committee meeting marks a critical milestone in the potential approval of this first-in-class therapy. With limited treatment options currently available for DMD, the success of Deramiocel could significantly impact the rare disease market and provide hope for patients and their families.

What we're watching

Regulatory Approval: Whether the FDA advisory committee's review will lead to a favorable recommendation for Deramiocel's approval.
Clinical Efficacy: The long-term impact of Deramiocel's clinically meaningful, statistically significant skeletal and cardiac benefits on patient outcomes.
Market Potential: The pace at which Capricor can commercialize Deramiocel if approved, given the urgent needs of the DMD community.